-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNOME ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL EVALUATING IM-3050, AN FAP-TARGETED RADIOLIGAND THERAPY, IN PATIENTS WITH FAP-EXPRESSING ADVANCED SOLID TUMORS

Reuters·07/20/2026 11:30:00

Please log in to view news